Search

Zentalis Pharmaceuticals Inc

Open

3.79 -5.49

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

3.86

Max

4.07

Schlüsselkennzahlen

By Trading Economics

Einkommen

-42M

-78M

EPS

-0.59

Angestellte

106

EBITDA

-42M

-77M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+119.11% upside

Dividenden

By Acuity

Nächstes Ergebnis

6. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

47M

378M

Vorheriger Eröffnungskurs

9.28

Vorheriger Schlusskurs

3.79

Zentalis Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

8. Sept. 2026, 23:56 UTC

Compass Minerals International Inc shares are lower in after-market hours, with no specific news identified. Broader market expectations for an interest rate hike persist.

8. Sept. 2026, 23:56 UTC

Pacific Biosciences of California Inc. shares are higher in after-market trading, despite fluctuations, and remain above their 20-day moving average.

8. Sept. 2026, 23:56 UTC

NextDecade Corp shares gained slightly in after-market trading. The stock remains above its 20-day moving average amid broader economic influences.

8. Sept. 2026, 23:56 UTC

Arrow Financial Corp shares are lower in after-market hours with no specific news identified. The stock has recovered from an initial decline.

8. Sept. 2026, 23:56 UTC

Qualys Inc shares are lower in after-market trading amid broader market weakness. The stock has declined for three consecutive sessions.

8. Sept. 2026, 23:56 UTC

Correlated Moves

Illinois Tool Works Inc shares are lower in after-market trading, reflecting broader industrial sector trends and influenced by declines in Lincoln Electric Holdings Inc.

8. Sept. 2026, 23:56 UTC

PPL Corp shares are higher in after-market trading, reflecting broader market sentiment following a strong jobs report that raised interest rate hike expectations.

8. Sept. 2026, 23:56 UTC

Correlated Moves

Samsara Inc shares are lower in after-market hours, influenced by ServiceTitan Inc's significant drop and broader market concerns over potential interest rate hikes.

8. Sept. 2026, 23:56 UTC

News

Korn Ferry's Board declared a quarterly cash dividend of $0.55 per share, payable October 15. Shares traded roughly flat in after-market hours.

8. Sept. 2026, 23:56 UTC

Mastercraft Boat Holdings Inc. shares were roughly flat in after-market hours, reflecting minimal price movement amid ongoing performance challenges.

8. Sept. 2026, 23:56 UTC

Comcast Corp shares are lower in after-market trading, following a session low. Recent economic data has influenced market expectations for potential interest rate hikes.

8. Sept. 2026, 23:56 UTC

Brown & Brown Inc shares are lower in after-market hours, reflecting broader market concerns over a potential interest rate hike following a strong jobs report.

8. Sept. 2026, 23:56 UTC

Cytokinetics Inc shares are higher in after-market trading, reflecting broader market sentiment following a strong jobs report and rising interest rate expectations.

8. Sept. 2026, 23:56 UTC

Social Media
News

Chevron Corp shares are higher in after-market hours following a report on declining OECD strategic petroleum reserves, which may impact oil prices and benefit the company.

8. Sept. 2026, 23:52 UTC

Ovid Therapeutics Inc is higher in after-market trading, reflecting positive momentum since Tuesday's close and positioning above its 20-day moving average.

8. Sept. 2026, 23:52 UTC

Cardinal Health Inc shares are lower in after-market hours, with volatility noted despite no specific company news or developments influencing the decline.

8. Sept. 2026, 23:51 UTC

CVR Energy Inc shares are higher in after-market trading, recovering from earlier volatility. Rising crude oil prices may be influencing market dynamics.

8. Sept. 2026, 23:51 UTC

Harley-Davidson Inc shares are higher in after-market trading, reflecting volatility amid rising crude oil prices and inflation concerns following a strong jobs report.

8. Sept. 2026, 23:51 UTC

Huron Consulting Group Inc shares are lower in after-market trading, retracing from an earlier session high and remaining below the 20-day moving average.

8. Sept. 2026, 23:51 UTC

Range Resources Corp shares are higher in after-market trading, buoyed by rising crude oil prices nearing $99 per barrel and a strong jobs report.

8. Sept. 2026, 23:51 UTC

Gold Resource Corp shares are lower in after-market hours amid rising crude oil prices and inflation concerns ahead of the Federal Reserve meeting.

8. Sept. 2026, 23:51 UTC

Brazil's Retail Sales MoM report on September 15, 2026, expected to reveal consumer spending trends and impact economic growth outlook.

8. Sept. 2026, 23:51 UTC

South Korea's unemployment rate drops to 2.7% in August, signaling strong job growth and positive investor sentiment amidst global economic uncertainties.

8. Sept. 2026, 23:51 UTC

Japan's July Machinery Orders Expected to Reflect Positive Capital Spending Trends Amidst Economic Recovery and Investor Optimism

8. Sept. 2026, 23:51 UTC

Japan's Trade Balance Data Release on September 15, 2026: Market Braces for Persistent Deficits Amid Weak Yen and Geopolitical Tensions.

8. Sept. 2026, 23:51 UTC

Japan's upcoming exports data release on September 15, 2026, is anticipated to reflect continued reliance on high-tech products amid positive economic indicators and rising real wages, despite global market uncertainties.

8. Sept. 2026, 23:51 UTC

Ambarella Inc. showed unusual strength in after-market trading, advancing despite rising crude oil prices and inflation concerns. No specific news was identified for the move.

8. Sept. 2026, 23:51 UTC

ETSY Inc. shares are higher in after-market trading, despite remaining below the 20-day moving average and near the lower end of the one-month range.

8. Sept. 2026, 23:51 UTC

Shares of United Airlines Holdings Inc. are higher in after-market trading, though they remain below the 20-day moving average and near the one-month range low.

8. Sept. 2026, 23:51 UTC

Illumina Inc shares are higher in after-market trading, showing notable activity and positioning above the 20-day moving average amid a lack of specific news.

Peer-Vergleich

Kursveränderung

Zentalis Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

119.11% Vorteil

12-Monats-Prognose

Durchschnitt 8.83 USD  119.11%

Hoch 11 USD

Tief 5 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Zentalis Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

6 ratings

5

Buy

1

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat